In your interventional cardiology practice, which markers of risk, in the patient who has undergone a PCI, do you focus on to promote consideration for using a PCSK9 inhibitor?

In your interventional cardiology practice, which markers of risk, in the patient who has undergone a PCI, do you focus on to promote consideration for using a PCSK9 inhibitor?

In your interventional cardiology practice, which markers of risk, in the patient who has undergone a PCI, do you focus on to promote consideration for using a PCSK9 inhibitor?z


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Ulf Landmesser MD, FESC

Ulf Landmesser MD, FESC

Professor of Cardiology Medical Director, Department of Cardiology Charite University Hospital Berlin, Germany